Summary
GBI Research has
released the pharma report, "ADHD Therapeutics to 2020 - Broadened
Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite
Patent Expirations" Changes in diagnostic criteria have reduced the
symptom threshold for diagnosis and finally bring the acceptance of adult ADHD
to the clinical setting, enabling those previously unable to obtain a diagnosis
to be diagnosed for ADHD treatment. In the case of adult ADHD, 4.1% of US
adults are believed to suffer from ADHD, 41.3% of these cases are classified as
severe and would be eligible for therapeutic intervention.
The current ADHD
therapeutics market is flooded with generics and dominated by the use of
Extended-Release (ER) stimulant drugs which have superseded short-acting,
Immediate-Release (IR) formulations. With dose titration per patient, ER
stimulants are usually effective in 70-90% of patients. However, all stimulants
apart from Vyvanse come with potential for abuse. Non-stimulants are used for
those who are poor-responders, have poor cardiac history or prefer
non-stimulant medication however their efficacy is lacking in comparison.
Currently, 10% of adult patients are using a combination of ER and IR treatment
for an additional duration, representing an unmet need within this growing ADHD
segment.
To Get More Details @ http://www.radiantinsights.com/research/adhd-therapeutics-to-2020-broadened-diagnostic-criteria-and-growing-adult-prevalence-to-drive-market-growth-despite-patent-expirations
The current
developmental pipeline addresses these gaps in the market, with three potential
non-stimulants entering the market during the forecast period and SHP465, which
aims to address the unmet need in the adult ADHD segment with its tailored
duration of action. In spite of anticipated drug approvals, patents expirations
and increased generic competition will cause ACoT to remain fairly static and
even decrease across some nations.
As a result, the global
market is not expected to be driven by drug approvals, but primarily by a
growing prevalence, increase in rates of diagnosis, and therefore eligible
treatment population. Global market revenues are forecast to rise at a CAGR of
4.8% to $9.4 billion by 2020.
About Radiant Insights
Radiant Insights is a platform for companies looking to meet
their market research and business intelligence requirements. We assist and
facilitate organizations and individuals procure market research reports,
helping them in the decision making process. We have a comprehensive collection
of reports, covering over 40 key industries and a host of micro markets. In
addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research
partnerships/ tie-ups and customized research solutions.
For More Information Visit – Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
No comments:
Post a Comment